WO2025136341A1 - A tablet comprising brexpiprazole - Google Patents
A tablet comprising brexpiprazole Download PDFInfo
- Publication number
- WO2025136341A1 WO2025136341A1 PCT/TR2024/051657 TR2024051657W WO2025136341A1 WO 2025136341 A1 WO2025136341 A1 WO 2025136341A1 TR 2024051657 W TR2024051657 W TR 2024051657W WO 2025136341 A1 WO2025136341 A1 WO 2025136341A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tablet
- tablet according
- sodium
- cellulose
- brexpiprazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Definitions
- the present invention relates to a tablet comprises brexpiprazole or a salt thereof and at least one pharmaceutically acceptable excipient wherein sodium stearyl fumarate is present as lubricant. Further, the present invention also relates to a simple, rapid, cost effective, time-saving and industrially convenient process.
- the main object of the present invention is to provide a tablet comprising brexpiprazole with content uniformity and high stability.
- Another object of the present invention is to provide a tablet comprising brexpiprazole having desired level of dissolution profile.
- Another object of the present invention is to provide a process for preparing a tablet comprising brexpiprazole which is simple and rapid, cost effective, time-saving and industrially convenient process.
- a tablet comprises brexpiprazole or a salt thereof and at least one pharmaceutically acceptable excipient wherein sodium stearyl fumarate is present as lubricant.
- the amount of lubricant in the tablet is 0.1% to 3.0% by weight of the total composition.
- the amount of brexpiprazole or a salt thereof is between 0.1% and 10.0% by weight of the total composition.
- brexpiprazole or a salt thereof having the following particle sizes is very important for formulation. Especially, it positively affects the dissolution properties.
- the obtained tablets have the desired dissolution profile.
- 'particle size means the cumulative volume size distrubition as tested by any conventionally accepted method such as the laser diffraction method (i.e. Malvern Mastersizer 2000 analysis).
- d (0.9) means the size at which %90 by volume of the particles are finer.
- brexpiprazole or a salt thereof has a d (0.9) particle size between 1 pm and 35 pm, more preferably between 3 pm and 27 pm.
- the tablet comprises at least one pharmaceutically acceptable excipient which is selected from the group comprising fillers, binders, disintegrants, lubricants or mixtures thereof.
- Suitable fillers are selected from group comprising lactose monohydrate, microcrystalline cellulose, mannitol, pregelatinized starch, ammonium alginate, calcium carbonate, lactose anhydrous, calcium phosphate, calcium phosphate dehydrate, neutral pellets, calcium sulfate, cellulose, ethylcellulose, fructose, glyceryl palmitostearate, magnesium carbonate, magnesium oxide, maltodextrin, maltose, medium chain triglycerides, polydextrose, polymethacrylates, sodium alginate, sodium chloride, sorbitol, starch, sucrose, sugar sphericals , polysorbate 80, xylitol or mixtures thereof.
- filler is lactose monohydrate, microcrystalline cellulose, lactose anhydrous or mixtures thereof. According to this embodiment of the present invention, filler is lactose monohydrate and microcrystalline cellulose.
- filler is lactose anhydrous and microcrystalline cellulose.
- the amount of filler in the tablet is 80.0% to 95.0% by weight of the total composition. Preferably, it is 86.0% to 92.0% by weight of the total composition.
- a process for preparing a tablet comprising brexpiprazole or a salt thereof comprises the below following steps; a) Mixing used fillers, b) Mixing brexpiprazole, at least one binder and at least one disintegrant, c) Mixing the mixture at step (a) and the mixture at step (b) with geometric dilution d) Sieving the mixture and then mixing, e) Adding sodium stearyl fumarate and then mixing, f) Compressing the total mixture into tablet.
- Example 1 Tablet
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a tablet comprises brexpiprazole or a salt thereof and at least one pharmaceutically acceptable excipient wherein sodium stearyl fumarate is present as lubricant. Further, the present invention also relates to a simple, rapid, cost effective, time-saving and industrially convenient process.
Description
A TABLET COMPRISING BREXPIPRAZOLE
Field of the Invention
The present invention relates to a tablet comprises brexpiprazole or a salt thereof and at least one pharmaceutically acceptable excipient wherein sodium stearyl fumarate is present as lubricant. Further, the present invention also relates to a simple, rapid, cost effective, time-saving and industrially convenient process.
Background of the Invention
Brexpiprazole acts as a partial agonist of the serotonin 5-HT1A receptor and the dopamine D2 and D3 receptors. Brexpiprazole has been described for use in the treatment of schizophrenia, depression and other central nervous system disorders, and for use in the prophylaxis and/or treatment of behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease.
Brexpiprazole is a compound represented by the following Formula I, and its chemical name is 7-[4-
[4-(l-benzothiophen-4-yl)piperazin-l-yl]butoxy]-lH-quinolin-2-one.
Formula I
Brexpiprazole is an antidepressant and antipsychotic drug marketed under the brand Rexulti® for the oral treatment of schizophrenia and as an adjunctive treatment to antidepressants in major depressive disorder. REXULTI tablets are intended for oral administration and available in 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg strengths. The product was approved in the U.S. in 2015 for the aforementioned indications and is currently in phase III trials for the treatment of agitation associated with Alzheimer's disease and the treatment of PTSD (post-traumatic stress disorder).
Brexpiprazole has poor solubility in water. The major limitation of the drug is its low solubility. So, in a formulation comprising brexpiprazole, solubility is important.
WO2019121849 patent application relates to a pharmaceutical composition in the form of a tablet, comprising a) brexpiprazole as active ingredient and b) at least 5% by weight (wt%) pregelatinized
starch (PGS). The invention relates to methods of preparing the tablet comprising dry granulation of a blend of the components to produce granules and compression of the granules to a tablet.
EP3545950A1 patent application relates to a pharmaceutical composition comprising a granulate comprising brexpiprazole, wherein the granulate is obtained by wet-granulation of a carrier using a granulation liquid that is a solution of brexpiprazole in a solvent system.
In prior art, low solubility of brexpiprazole has been approached in several ways. However, we have seen that studies carried out to correct the dissolution profile may cause some stability problems.
As evident from the prior art and the literature there are reported several pharmaceutical compositions comprising brexpiprazole. There is an existing and continual need for oral dosage formulations comprising brexpiprazole or a pharmaceutically acceptable salt thereof that have high stability, content uniformity, improved compressibility, flowability and manufactured by safe, effective, easy manufacturing methods.
We have found that the tablet comprising brexpiprazole or a salt thereof and sodium stearyl fumarate as lubricant, it positively affects the desired high stability. The obtained tablets have also the desired dissolution profile and homogeneous. The tablet has been developed by using standard techniques which is simple and cost-effective method.
Detailed Description of the Invention
The main object of the present invention is to provide a tablet comprising brexpiprazole with content uniformity and high stability.
Another object of the present invention is to provide a tablet comprising brexpiprazole having desired level of dissolution profile.
Another object of the present invention is to provide a process for preparing a tablet comprising brexpiprazole which is simple and rapid, cost effective, time-saving and industrially convenient process.
As it is known, the use of lubricant provides excellent flowability of powders during process comprising brexpiprazole. We have also seen in the present invention that the use of sodium stearyl fumarate shows good stability to the tablet.
When a tablet comprising brexpiprazole was formulated with sodium stearyl fumarate, we seen that positively affects the high stability and powder homogenization. The obtained tablets have the
desired dissolution profile. The powder is more homogeneous. The content uniformity of the tablets obtained from the more homogeneous powder is more ideal. Therefore, it provides better bioavailability.
According to one embodiment of the present invention, a tablet comprises brexpiprazole or a salt thereof and at least one pharmaceutically acceptable excipient wherein sodium stearyl fumarate is present as lubricant.
According to this embodiment of the present invention, the amount of lubricant in the tablet is 0.1% to 3.0% by weight of the total composition.
According to one embodiment of the present invention, the amount of brexpiprazole or a salt thereof is between 0.1% and 10.0% by weight of the total composition.
We see that brexpiprazole or a salt thereof having the following particle sizes is very important for formulation. Especially, it positively affects the dissolution properties. The obtained tablets have the desired dissolution profile.
As used here in, 'particle size' means the cumulative volume size distrubition as tested by any conventionally accepted method such as the laser diffraction method (i.e. Malvern Mastersizer 2000 analysis). The term d (0.9) means the size at which %90 by volume of the particles are finer.
In one embodiment of the invention, brexpiprazole or a salt thereof has a d (0.9) particle size between 1 pm and 35 pm, more preferably between 3 pm and 27 pm.
According to this embodiment of the present invention, the tablet comprises at least one pharmaceutically acceptable excipient which is selected from the group comprising fillers, binders, disintegrants, lubricants or mixtures thereof.
Suitable fillers are selected from group comprising lactose monohydrate, microcrystalline cellulose, mannitol, pregelatinized starch, ammonium alginate, calcium carbonate, lactose anhydrous, calcium phosphate, calcium phosphate dehydrate, neutral pellets, calcium sulfate, cellulose, ethylcellulose, fructose, glyceryl palmitostearate, magnesium carbonate, magnesium oxide, maltodextrin, maltose, medium chain triglycerides, polydextrose, polymethacrylates, sodium alginate, sodium chloride, sorbitol, starch, sucrose, sugar sphericals , polysorbate 80, xylitol or mixtures thereof.
According to this embodiment of the present invention, filler is lactose monohydrate, microcrystalline cellulose, lactose anhydrous or mixtures thereof.
According to this embodiment of the present invention, filler is lactose monohydrate and microcrystalline cellulose.
According to this embodiment of the present invention, filler is lactose anhydrous and microcrystalline cellulose.
According to this embodiment of the present invention, the amount of filler in the tablet is 80.0% to 95.0% by weight of the total composition. Preferably, it is 86.0% to 92.0% by weight of the total composition.
Suitable binders are selected from the group comprising polyvinylpyrrolidone, carboxymethylcellulose sodium, sugars, agar, alginates, carbomers, cellulose acetate phthalate, chitosan, starch, starch mucilage, acacia mucilage, dextrates, dextrin, dextrose, ethylcellulose, glyceryl behenate, hydrogenated vegetable oil type I, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, hydroxypropyl starch, hypromellose, magnesium aluminum silicate, maltodextrin, methylcellulose, poloxamer, polycarbophil, polydextrose, polyethylene oxide, polymethacrylates, aluminia hydroxide, stearic acid, sucrose, , polyoxyethilene-alkyl ethers, pullulan or mixtures thereof.
According to this embodiment of the present invention, the binder is polyvinylpyrrolidone or hydroxypropyl cellulose or mixtures thereof.
According to this embodiment of the present invention, the amount of binder in the tablet is 1.0% to 10.0% by weight of the total composition. Preferably, it is 2.0% to 6.0% by weight of the total composition.
Suitable disintegrants are selected from the group comprising sodium starch glycolate, crospovidone, cross-linked carboxymethyl cellulose (croscarmellose sodium), low-substituted hydroxypropyl cellulose, carboxymethyl cellulose, docusate sodium, guar gum, sodium alginate, alginic acid, magnesium aluminium silica, poloxamer, sodium glycine carbonate or mixtures thereof.
According to this embodiment of the present invention, the disintegrant is crospovidone.
According to this embodiment of the present invention, the amount of disintegrant in the tablet is 2.0% to 10.0% by weight, preferably 2.5% to 6.0% by weight, more preferably 2.8% to 5.5% by weight of the total composition. The disintegrant ratio provided the desired dissolution profile and high stability in the tablet while also ensuring homogeneity.
According to this embodiment of the present invention, the said tablet is used as a core tablet, which is then coated with a film coating to obtain a film-coated tablet form. Film coating is based on HPMC or PVA.
According to this embodiment of the present invention, the said tablet is used as mini-tablets, which is then filled into a capsule. Mini tablets of 0.25 mg dose are placed in different capsules, providing easy access to each dose brexpiprazole product.
According to this embodiment of the present invention, the tablet comprises;
■ Brexpiprazole or a salt thereof having particle size d90 less than about 35 microns,
■ Hydroxypropyl Cellulose or polyvinylpyrrolidone
■ Crospovidone
■ Sodium stearyl fumarate
According to this embodiment of the present invention, the tablet comprises;
■ Brexpiprazole or a salt thereof having particle size d90 less than about 35 microns,
■ Lactose monohydrate or lactose anhydrous
■ Microcrystalline cellulose
■ Crospovidone
■ Sodium stearyl fumarate
According to this embodiment of the present invention, the tablet is prepared direct compression or compaction method which is simple and cost-effective method. These processes are solvent-free, which helps to stabilize the active ingredient and thus the stability of the tablet.
According to this embodiment of the present invention, a process for preparing a tablet comprising brexpiprazole or a salt thereof comprises the below following steps; a) Mixing used fillers, b) Mixing brexpiprazole, at least one binder and at least one disintegrant, c) Mixing the mixture at step (a) and the mixture at step (b) with geometric dilution d) Sieving the mixture and then mixing, e) Adding sodium stearyl fumarate and then mixing, f) Compressing the total mixture into tablet.
Example 1: Tablet
A process for example 1; a) Mixing lactose monohydrate or lactose anhydrous and microcrystalline cellulose, b) Mixing brexpiprazole, polyvinylpyrrolidone and crospovidone, c) Mixing the mixture at step (a) and the mixture at step (b) with geometric dilution d) Sieving the mixture into 0.9 mm and then mixing, e) Adding sodium stearyl fumarate and then mixing, f) Compressing the total mixture into tablet.
Preferably, the tablet is present in the form of mini-tablets, and the mini tablets is filled into capsule. Preferably, the tablet is coating with film coating to obtained film coated tablet.
A process for example 1; a) Mixing lactose monohydrate or lactose anhydrous and microcrystalline cellulose, b) Mixing brexpiprazole, polyvinylpyrrolidone, crospovidone and the half of sodium stearyl fumarate, c) Mixing the mixture at step (a) and the mixture at step (b) with geometric dilution d) Sieving the mixture into 0.9 mm and then mixing, e) Compacting the mixture with compaction machine, f) Adding the remaining part of sodium stearyl fumarate and then mixing, g) Compressing the total mixture into tablet.
Preferably, the tablet is present in the form of mini-tablets, and the mini tablets is filled into capsule.
Preferably, the tablet is coating with film coating to obtained film coated tablet.
Example 2: Tablet
A process for example 2; a) Mixing lactose monohydrate or lactose anhydrous and microcrystalline cellulose, b) Mixing brexpiprazole, HPC and crospovidone, c) Mixing the mixture at step (a) and the mixture at step (b) with geometric dilution d) Sieving the mixture into 0.9 mm and then mixing, e) Adding sodium stearyl fumarate and then mixing, f) Compressing the total mixture into tablet.
Preferably, the tablet is present in the form of mini-tablets, and the mini tablets is filled into capsule.
Preferably, the tablet is coating with film coating to obtained film coated tablet.
Claims
1) A tablet comprises brexpiprazole or a salt thereof and at least one pharmaceutically acceptable excipient wherein sodium stearyl fumarate is present as lubricant.
2) The tablet according to claim 1, wherein brexpiprazole or a salt thereof has a d (0.9) particle size between 1 pm and 35 pm, more preferably between 3 pm and 27 pm.
3) The tablet according to claim 1, wherein the tablet comprises at least one pharmaceutically acceptable excipient which is selected from the group comprising fillers, binders, disintegrants, lubricants or mixtures thereof.
4) The tablet according to claim 3, wherein fillers are selected from group comprising lactose monohydrate, microcrystalline cellulose, mannitol, pregelatinized starch, ammonium alginate, calcium carbonate, lactose anhydrous, calcium phosphate, calcium phosphate dehydrate, neutral pellets, calcium sulfate, cellulose, ethylcellulose, fructose, glyceryl palmitostearate, magnesium carbonate, magnesium oxide, maltodextrin, maltose, medium chain triglycerides, polydextrose, polymethacrylates, sodium alginate, sodium chloride, sorbitol, starch, sucrose, sugar sphericals , polysorbate 80, xylitol or mixtures thereof.
5) The tablet according to claim 3, wherein filler is lactose monohydrate, microcrystalline cellulose, lactose anhydrous or mixtures thereof.
6) The tablet according to claim 3, wherein binders are selected from the group comprising polyvinylpyrrolidone, carboxymethylcellulose sodium, sugars, agar, alginates, carbomers, cellulose acetate phthalate, chitosan, starch, starch mucilage, acacia mucilage, dextrates, dextrin, dextrose, ethylcellulose, glyceryl behenate, hydrogenated vegetable oil type I, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, hydroxypropyl starch, hypromellose, magnesium aluminum silicate, maltodextrin, methylcellulose, poloxamer, polycarbophil, polydextrose, polyethylene oxide, polymethacrylates, aluminia hydroxide, stearic acid, sucrose, , polyoxyethilene-alkyl ethers, pullulan or mixtures thereof.
7) The tablet according to claim 3, wherein the binder is polyvinylpyrrolidone or hydroxypropyl cellulose or mixtures thereof.
8) The tablet according to claim 3, wherein disintegrants are selected from the group comprising sodium starch glycolate, crospovidone, cross-linked carboxymethyl cellulose (croscarmellose sodium), low-substituted hydroxypropyl cellulose, carboxymethyl cellulose,
docusate sodium, guar gum, sodium alginate, alginic acid, magnesium aluminium silica, poloxamer, sodium glycine carbonate or mixtures thereof.
9) The tablet according to claim 3, wherein the disintegrant is crospovidone.
10) The tablet according to claim 9, wherein the amount of disintegrant in the tablet is 2.0% to 10.0% by weight, preferably 2.5% to 6.0% by weight.
11) The tablet according to claim 1, wherein the said tablet is used as a core tablet, which is then coated with a film coating to obtain a film-coated tablet form.
12) The tablet according to claim 1, wherein the said tablet is used as mini-tablets, which is then filled into a capsule.
13) The tablet according to claim 1 or 3, wherein the tablet comprising;
■ Brexpiprazole or a salt thereof having particle size d90 less than about 35 microns,
■ Hydroxypropyl Cellulose or polyvinylpyrrolidone
■ Crospovidone
■ Sodium stearyl fumarate
14) The tablet according to claim 1 or 3, wherein the tablet comprising;
■ Brexpiprazole or a salt thereof having particle size d90 less than about 35 microns,
■ Lactose monohydrate or lactose anhydrous
■ Microcrystalline cellulose
■ Crospovidone
■ Sodium stearyl fumarate
15) The tablet according to any preceding claims, wherein the said tablet is used as mini-tablets, which is then filled into a capsule.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2023/018022 | 2023-12-22 | ||
| TR2023/018022A TR2023018022A1 (en) | 2023-12-22 | 2023-12-22 | A TABLET CONTAINING BREXPIPRAZOL |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2025136341A1 true WO2025136341A1 (en) | 2025-06-26 |
Family
ID=96137835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/TR2024/051657 Pending WO2025136341A1 (en) | 2023-12-22 | 2024-12-20 | A tablet comprising brexpiprazole |
Country Status (2)
| Country | Link |
|---|---|
| TR (1) | TR2023018022A1 (en) |
| WO (1) | WO2025136341A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012137971A1 (en) * | 2011-04-05 | 2012-10-11 | Otsuka Pharmaceutical Co., Ltd. | Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a cns disorder |
| WO2018033481A1 (en) * | 2016-08-16 | 2018-02-22 | H E X A L Aktiengesellschaft | Immediate release tablet of a benzothiophene compound |
| EP3501506A1 (en) * | 2017-12-19 | 2019-06-26 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pharmaceutical tablet composition comprising brexpiprazole |
-
2023
- 2023-12-22 TR TR2023/018022A patent/TR2023018022A1/en unknown
-
2024
- 2024-12-20 WO PCT/TR2024/051657 patent/WO2025136341A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012137971A1 (en) * | 2011-04-05 | 2012-10-11 | Otsuka Pharmaceutical Co., Ltd. | Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a cns disorder |
| WO2018033481A1 (en) * | 2016-08-16 | 2018-02-22 | H E X A L Aktiengesellschaft | Immediate release tablet of a benzothiophene compound |
| EP3501506A1 (en) * | 2017-12-19 | 2019-06-26 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pharmaceutical tablet composition comprising brexpiprazole |
Also Published As
| Publication number | Publication date |
|---|---|
| TR2023018022A1 (en) | 2025-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2020058095A1 (en) | Pharmaceutical compositions of empagliflozin | |
| US10918604B2 (en) | Solid oral dosage forms of eslicarbazepine | |
| WO2017195144A1 (en) | Pharmaceutical compositions comprising brivaracetam | |
| EP2291079B1 (en) | Formulations for cathepsin k inhibitors | |
| CA3092948C (en) | Pharmaceutical composition comprising brexpiprazole | |
| WO2023059296A1 (en) | A tablet comprising micronized brexpiprazole | |
| EA023340B1 (en) | Ropinirole composition | |
| WO2023111187A1 (en) | Pharmaceutical compositions comprising eltrombopag | |
| KR102612983B1 (en) | Composite capsules with improved dissolution rate comprising raloxifene, and Vitamin D or its derivatives,and preparing method thereof | |
| RU2613192C1 (en) | Tablets of clozapine with sustained release | |
| KR102548747B1 (en) | Composite capsules comprising raloxifene, and Vitamin D or its derivatives | |
| EP2644197A1 (en) | Novel Pharmaceutical Compositions of Entecavir | |
| WO2025136341A1 (en) | A tablet comprising brexpiprazole | |
| US20180344648A1 (en) | Clobazam tablet formulation and process for its preparation | |
| EP4574134A1 (en) | A tablet comprising brexpiprazole | |
| WO2025136342A1 (en) | Tablets comprising brexpiprazole | |
| EP4574135A1 (en) | Tablets comprising brexpiprazole | |
| JP7492370B2 (en) | Fingolimod hydrochloride-containing preparation and method for producing the preparation | |
| JP6731136B2 (en) | Pharmaceutical formulation | |
| EP4374856A1 (en) | A process for tablets comprising brexpiprazole | |
| TR2022017701A1 (en) | A PROCESS FOR TABLETS CONTAINING BREXPIPRAZole | |
| EP4412595A1 (en) | A tablet comprising micronized brexpiprazole | |
| KR102373089B1 (en) | Pharmaceutical composition comprising ibuprofen and acetaminophen and preparation method thereof | |
| EP2644196B1 (en) | Pharmaceutical compositions of Entecavir | |
| JP7115825B2 (en) | Oral formulation containing ezetimibe and its manufacturing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 24908500 Country of ref document: EP Kind code of ref document: A1 |